Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HGP1602 in Healthy Subjects
NCT04084184Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Mar 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration of Dapagliflozin and Area Under the Curve to the Last Quantifiable Concentration. Started Mar 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04084184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04084184.